Inhibikase Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Inhibikase Therapeutics

15/11/2022 24:43

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 18 cents​​ per share for the quarter ended in
September. The lone analyst forecast for the quarter was for a
loss of 18 cents per share.
    * Revenue fell 97.8% to $7.29 thousand from a year ago;
analysts
expected $200.00 thousand. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 18 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Inhibikase Therapeutics Inc shares had fallen by 45.1%
this
quarter and lost 66.0% so far this year.
    * The company reported a quarterly loss of $4.49 million.
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
15 at 12:43 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.18          -0.18          Met
 Jun. 30 2022      -0.19          -0.18          Beat
 Mar. 31 2022      -0.17          -0.18          Missed
 Dec. 31 2021      -0.17          -0.20          Missed